Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Joseph C. Glorioso

University of Pittsburgh at Pittsburgh, Department: Neurosurgery

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Oncorus

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

Dr. Glorioso's conflict arises due to his interest as an inventor of intellectual property being evaluated/developed in bench research funded by this grant, which the University of Pittsburgh licensed to Oncorus. Dr. Glorioso also consults for Oncorus and has an ownership interest in the company.

Listed Research Project
Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector

Glioblastoma multiforme (GBM) is a deadly brain tumor without effective therapy. Oncolytic herpes simplex viral vectors (OVs) provide an attractive treatment alternative however clinical trials have thus far been disappointing. We propose to create a new oHSV that is not compromised for growth through attenuating mutagenesis but rather our vector will be essentially a wild type virus in order to ensure the most robust virus replication and lytic activity in tumor cells. We will ensure vector safety and tumor specificity b engineering this new oHSV to utilize tumor related receptors and limit growth in normal tissue through cellular microRNA control of vector growth. We anticipate that this new vector design will be far more effective in tumor treatment and can be developed for patient trials.

Filed on June 21, 2017.

Tell us what you know about Joseph C. Glorioso's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Joseph Glorioso University of Pittsburgh at Pittsburgh Conflict of Interest Oncorus, Inc. $100,000 - $149,999
Joseph C. Glorioso University of Pittsburgh at Pittsburgh Conflict of Interest Oncorus $100,000 - $149,999
Joseph C. Glorioso University of Pittsburgh at Pittsburgh Conflict of Interest Oncorus $5,000 - $9,999
Joseph Glorioso University of Pittsburgh at Pittsburgh Conflict of Interest Oncorus, Inc. Value cannot be readily determined
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page